← All Goodrx Holdings, INC filings

Goodrx Holdings, INC 8-K filings

NASDAQ
GDRX
Goodrx Holdings, INC
8-K: GoodRx Reports Mixed Results for Q4 and Full Year 2023, Announces New Share Repurchase Program
GoodRx's fourth quarter and full year 2023 results show revenue growth and improved profitability metrics, alongside a new $450 million share repurchase program.
NASDAQ
GDRX
Goodrx Holdings, INC
8-K: GoodRx Extends Credit Facility Maturity and Finalizes COO Departure
GoodRx has extended the maturity date of its $100 million revolving credit facility and finalized a separation agreement with its former Chief Operating Officer.
NASDAQ
GDRX
Goodrx Holdings, INC
8-K: GoodRx Holdings Eliminates Chief Operating Officer Role, CEO Assumes Responsibilities
GoodRx Holdings has eliminated the Chief Operating Officer role, with the CEO taking on those responsibilities effective February 15, 2024.